Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age
Vaccination is the best measure to prevent influenza. We conducted a cost-effectiveness evaluation of trivalent inactivated seasonal influenza vaccination, compared to no vaccination, in children ≤60 months of age participating in a prospective cohort study in Bangkok, Thailand. A static decision tr...
Gespeichert in:
| Veröffentlicht in: | PloS one 2017-08, Vol.12 (8), p.e0183391-e0183391 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0183391 |
|---|---|
| container_issue | 8 |
| container_start_page | e0183391 |
| container_title | PloS one |
| container_volume | 12 |
| creator | Kittikraisak, Wanitchaya Suntarattiwong, Piyarat Ditsungnoen, Darunee Pallas, Sarah E Abimbola, Taiwo O Klungthong, Chonticha Fernandez, Stefan Srisarang, Suchada Chotpitayasunondh, Tawee Dawood, Fatimah S Olsen, Sonja J Lindblade, Kim A |
| description | Vaccination is the best measure to prevent influenza. We conducted a cost-effectiveness evaluation of trivalent inactivated seasonal influenza vaccination, compared to no vaccination, in children ≤60 months of age participating in a prospective cohort study in Bangkok, Thailand.
A static decision tree model was constructed to simulate the population of children in the cohort. Proportions of children with laboratory-confirmed influenza were derived from children followed weekly. The societal perspective and one-year analytic horizon were used for each influenza season; the model was repeated for three influenza seasons (2012-2014). Direct and indirect costs associated with influenza illness were collected and summed. Cost of the trivalent inactivated seasonal influenza vaccine (IIV3) including promotion, administration, and supervision cost was added for children who were vaccinated. Quality-adjusted life years (QALY), derived from literature, were used to quantify health outcomes. The incremental cost-effectiveness ratio (ICER) was calculated as the difference in the expected total costs between the vaccinated and unvaccinated groups divided by the difference in QALYs for both groups.
Compared to no vaccination, IIV3 vaccination among children ≤60 months in our cohort was not cost-effective in the introductory year (2012 season; 24,450 USD/QALY gained), highly cost-effective in the 2013 season (554 USD/QALY gained), and cost-effective in the 2014 season (16,200 USD/QALY gained).
The cost-effectiveness of IIV3 vaccination among children participating in the cohort study varied by influenza season, with vaccine cost and proportion of high-risk children demonstrating the greatest influence in sensitivity analyses. Vaccinating children against influenza can be economically favorable depending on the maturity of the program, influenza vaccine performance, and target population. |
| doi_str_mv | 10.1371/journal.pone.0183391 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1932162294</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A501665523</galeid><doaj_id>oai_doaj_org_article_7d87bd2570db4b0d82f1905a5303857f</doaj_id><sourcerecordid>A501665523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-477a81b03fb3d38b5ebf6deca6a8d89d17ae9a069a74d5ac870a4beb5eb269753</originalsourceid><addsrcrecordid>eNqNk89u1DAQxiMEoqXwBggiISE47GLHsWNfKlUVf1aqVAkKV2tiT3a9ysbbOFkBb8B78GQ8CU43rTaoB5RD4snv-8YezyTJc0rmlBX03dr3bQP1fOsbnBMqGVP0QXJMFctmIiPs4cH3UfIkhDUhnEkhHidHmZSs4Co_Tq7PfehmWFVoOrfDBkNIfZW6BoY1dGjTgBB8zBSDVd1j8xPSHRgTkc75JkZTSI1f-bYblFcrcKlZudq22KR_fv0WJN34plvd-MISnyaPKqgDPhvfJ8nXD--vzj_NLi4_Ls7PLmZGqKyb5UUBkpaEVSWzTJYcy0pYNCBAWqksLQAVEKGgyC0HIwsCeYkDlwlVcHaSvNz7bmsf9FitoIeaUJFlKo_EYk9YD2u9bd0G2h_ag9M3Ad8uNbSdMzXqwsqitBkviC3zkliZVVQRDpwRJnlRRa_TMVtfbtAabLoW6onp9E_jVnrpd5pHz0wM230zGrT-usfQ6Y0LBusaGvT9ft8yF0qpiL76B73_dCO1hHiAeHc-5jWDqT7jhArBecYiNb-Hio_FjTOxtSoX4xPB24kgMh1-75bQh6AXXz7_P3v5bcq-PmBXCHVsGV_3Q4-FKZjvQdP6EFqs7opMiR4m47YaepgMPU5GlL04vKA70e0osL9ArApf</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932162294</pqid></control><display><type>article</type><title>Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Kittikraisak, Wanitchaya ; Suntarattiwong, Piyarat ; Ditsungnoen, Darunee ; Pallas, Sarah E ; Abimbola, Taiwo O ; Klungthong, Chonticha ; Fernandez, Stefan ; Srisarang, Suchada ; Chotpitayasunondh, Tawee ; Dawood, Fatimah S ; Olsen, Sonja J ; Lindblade, Kim A</creator><contributor>Ortiz, Justin R.</contributor><creatorcontrib>Kittikraisak, Wanitchaya ; Suntarattiwong, Piyarat ; Ditsungnoen, Darunee ; Pallas, Sarah E ; Abimbola, Taiwo O ; Klungthong, Chonticha ; Fernandez, Stefan ; Srisarang, Suchada ; Chotpitayasunondh, Tawee ; Dawood, Fatimah S ; Olsen, Sonja J ; Lindblade, Kim A ; Ortiz, Justin R.</creatorcontrib><description>Vaccination is the best measure to prevent influenza. We conducted a cost-effectiveness evaluation of trivalent inactivated seasonal influenza vaccination, compared to no vaccination, in children ≤60 months of age participating in a prospective cohort study in Bangkok, Thailand.
A static decision tree model was constructed to simulate the population of children in the cohort. Proportions of children with laboratory-confirmed influenza were derived from children followed weekly. The societal perspective and one-year analytic horizon were used for each influenza season; the model was repeated for three influenza seasons (2012-2014). Direct and indirect costs associated with influenza illness were collected and summed. Cost of the trivalent inactivated seasonal influenza vaccine (IIV3) including promotion, administration, and supervision cost was added for children who were vaccinated. Quality-adjusted life years (QALY), derived from literature, were used to quantify health outcomes. The incremental cost-effectiveness ratio (ICER) was calculated as the difference in the expected total costs between the vaccinated and unvaccinated groups divided by the difference in QALYs for both groups.
Compared to no vaccination, IIV3 vaccination among children ≤60 months in our cohort was not cost-effective in the introductory year (2012 season; 24,450 USD/QALY gained), highly cost-effective in the 2013 season (554 USD/QALY gained), and cost-effective in the 2014 season (16,200 USD/QALY gained).
The cost-effectiveness of IIV3 vaccination among children participating in the cohort study varied by influenza season, with vaccine cost and proportion of high-risk children demonstrating the greatest influence in sensitivity analyses. Vaccinating children against influenza can be economically favorable depending on the maturity of the program, influenza vaccine performance, and target population.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0183391</identifier><identifier>PMID: 28837594</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Age ; Armed forces ; Biology and Life Sciences ; Child, Preschool ; Children ; Children & youth ; Childrens health ; Cohort Studies ; Collaboration ; Computer simulation ; Cost-Benefit Analysis ; Decision Support Techniques ; Disease control ; Disease prevention ; Economic analysis ; Health aspects ; Health care expenditures ; Humans ; Immunization ; Infant ; Infectious diseases ; Influenza ; Influenza vaccines ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - economics ; Laboratories ; Medicine and Health Sciences ; Older people ; Pediatrics ; People and Places ; Prevention ; Promotion ; Prospective Studies ; Public health ; Quality-Adjusted Life Years ; Risk factors ; Seasons ; Sensitivity analysis ; Social Sciences ; Studies ; Thailand ; Vaccination ; Vaccines ; Virology</subject><ispartof>PloS one, 2017-08, Vol.12 (8), p.e0183391-e0183391</ispartof><rights>COPYRIGHT 2017 Public Library of Science</rights><rights>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-477a81b03fb3d38b5ebf6deca6a8d89d17ae9a069a74d5ac870a4beb5eb269753</citedby><cites>FETCH-LOGICAL-c692t-477a81b03fb3d38b5ebf6deca6a8d89d17ae9a069a74d5ac870a4beb5eb269753</cites><orcidid>0000-0002-2295-4388</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570265/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570265/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2929,23871,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28837594$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ortiz, Justin R.</contributor><creatorcontrib>Kittikraisak, Wanitchaya</creatorcontrib><creatorcontrib>Suntarattiwong, Piyarat</creatorcontrib><creatorcontrib>Ditsungnoen, Darunee</creatorcontrib><creatorcontrib>Pallas, Sarah E</creatorcontrib><creatorcontrib>Abimbola, Taiwo O</creatorcontrib><creatorcontrib>Klungthong, Chonticha</creatorcontrib><creatorcontrib>Fernandez, Stefan</creatorcontrib><creatorcontrib>Srisarang, Suchada</creatorcontrib><creatorcontrib>Chotpitayasunondh, Tawee</creatorcontrib><creatorcontrib>Dawood, Fatimah S</creatorcontrib><creatorcontrib>Olsen, Sonja J</creatorcontrib><creatorcontrib>Lindblade, Kim A</creatorcontrib><title>Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Vaccination is the best measure to prevent influenza. We conducted a cost-effectiveness evaluation of trivalent inactivated seasonal influenza vaccination, compared to no vaccination, in children ≤60 months of age participating in a prospective cohort study in Bangkok, Thailand.
A static decision tree model was constructed to simulate the population of children in the cohort. Proportions of children with laboratory-confirmed influenza were derived from children followed weekly. The societal perspective and one-year analytic horizon were used for each influenza season; the model was repeated for three influenza seasons (2012-2014). Direct and indirect costs associated with influenza illness were collected and summed. Cost of the trivalent inactivated seasonal influenza vaccine (IIV3) including promotion, administration, and supervision cost was added for children who were vaccinated. Quality-adjusted life years (QALY), derived from literature, were used to quantify health outcomes. The incremental cost-effectiveness ratio (ICER) was calculated as the difference in the expected total costs between the vaccinated and unvaccinated groups divided by the difference in QALYs for both groups.
Compared to no vaccination, IIV3 vaccination among children ≤60 months in our cohort was not cost-effective in the introductory year (2012 season; 24,450 USD/QALY gained), highly cost-effective in the 2013 season (554 USD/QALY gained), and cost-effective in the 2014 season (16,200 USD/QALY gained).
The cost-effectiveness of IIV3 vaccination among children participating in the cohort study varied by influenza season, with vaccine cost and proportion of high-risk children demonstrating the greatest influence in sensitivity analyses. Vaccinating children against influenza can be economically favorable depending on the maturity of the program, influenza vaccine performance, and target population.</description><subject>Age</subject><subject>Armed forces</subject><subject>Biology and Life Sciences</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Children & youth</subject><subject>Childrens health</subject><subject>Cohort Studies</subject><subject>Collaboration</subject><subject>Computer simulation</subject><subject>Cost-Benefit Analysis</subject><subject>Decision Support Techniques</subject><subject>Disease control</subject><subject>Disease prevention</subject><subject>Economic analysis</subject><subject>Health aspects</subject><subject>Health care expenditures</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Influenza</subject><subject>Influenza vaccines</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - economics</subject><subject>Laboratories</subject><subject>Medicine and Health Sciences</subject><subject>Older people</subject><subject>Pediatrics</subject><subject>People and Places</subject><subject>Prevention</subject><subject>Promotion</subject><subject>Prospective Studies</subject><subject>Public health</subject><subject>Quality-Adjusted Life Years</subject><subject>Risk factors</subject><subject>Seasons</subject><subject>Sensitivity analysis</subject><subject>Social Sciences</subject><subject>Studies</subject><subject>Thailand</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Virology</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk89u1DAQxiMEoqXwBggiISE47GLHsWNfKlUVf1aqVAkKV2tiT3a9ysbbOFkBb8B78GQ8CU43rTaoB5RD4snv-8YezyTJc0rmlBX03dr3bQP1fOsbnBMqGVP0QXJMFctmIiPs4cH3UfIkhDUhnEkhHidHmZSs4Co_Tq7PfehmWFVoOrfDBkNIfZW6BoY1dGjTgBB8zBSDVd1j8xPSHRgTkc75JkZTSI1f-bYblFcrcKlZudq22KR_fv0WJN34plvd-MISnyaPKqgDPhvfJ8nXD--vzj_NLi4_Ls7PLmZGqKyb5UUBkpaEVSWzTJYcy0pYNCBAWqksLQAVEKGgyC0HIwsCeYkDlwlVcHaSvNz7bmsf9FitoIeaUJFlKo_EYk9YD2u9bd0G2h_ag9M3Ad8uNbSdMzXqwsqitBkviC3zkliZVVQRDpwRJnlRRa_TMVtfbtAabLoW6onp9E_jVnrpd5pHz0wM230zGrT-usfQ6Y0LBusaGvT9ft8yF0qpiL76B73_dCO1hHiAeHc-5jWDqT7jhArBecYiNb-Hio_FjTOxtSoX4xPB24kgMh1-75bQh6AXXz7_P3v5bcq-PmBXCHVsGV_3Q4-FKZjvQdP6EFqs7opMiR4m47YaepgMPU5GlL04vKA70e0osL9ArApf</recordid><startdate>20170824</startdate><enddate>20170824</enddate><creator>Kittikraisak, Wanitchaya</creator><creator>Suntarattiwong, Piyarat</creator><creator>Ditsungnoen, Darunee</creator><creator>Pallas, Sarah E</creator><creator>Abimbola, Taiwo O</creator><creator>Klungthong, Chonticha</creator><creator>Fernandez, Stefan</creator><creator>Srisarang, Suchada</creator><creator>Chotpitayasunondh, Tawee</creator><creator>Dawood, Fatimah S</creator><creator>Olsen, Sonja J</creator><creator>Lindblade, Kim A</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2295-4388</orcidid></search><sort><creationdate>20170824</creationdate><title>Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age</title><author>Kittikraisak, Wanitchaya ; Suntarattiwong, Piyarat ; Ditsungnoen, Darunee ; Pallas, Sarah E ; Abimbola, Taiwo O ; Klungthong, Chonticha ; Fernandez, Stefan ; Srisarang, Suchada ; Chotpitayasunondh, Tawee ; Dawood, Fatimah S ; Olsen, Sonja J ; Lindblade, Kim A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-477a81b03fb3d38b5ebf6deca6a8d89d17ae9a069a74d5ac870a4beb5eb269753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Armed forces</topic><topic>Biology and Life Sciences</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Children & youth</topic><topic>Childrens health</topic><topic>Cohort Studies</topic><topic>Collaboration</topic><topic>Computer simulation</topic><topic>Cost-Benefit Analysis</topic><topic>Decision Support Techniques</topic><topic>Disease control</topic><topic>Disease prevention</topic><topic>Economic analysis</topic><topic>Health aspects</topic><topic>Health care expenditures</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Influenza</topic><topic>Influenza vaccines</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - economics</topic><topic>Laboratories</topic><topic>Medicine and Health Sciences</topic><topic>Older people</topic><topic>Pediatrics</topic><topic>People and Places</topic><topic>Prevention</topic><topic>Promotion</topic><topic>Prospective Studies</topic><topic>Public health</topic><topic>Quality-Adjusted Life Years</topic><topic>Risk factors</topic><topic>Seasons</topic><topic>Sensitivity analysis</topic><topic>Social Sciences</topic><topic>Studies</topic><topic>Thailand</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kittikraisak, Wanitchaya</creatorcontrib><creatorcontrib>Suntarattiwong, Piyarat</creatorcontrib><creatorcontrib>Ditsungnoen, Darunee</creatorcontrib><creatorcontrib>Pallas, Sarah E</creatorcontrib><creatorcontrib>Abimbola, Taiwo O</creatorcontrib><creatorcontrib>Klungthong, Chonticha</creatorcontrib><creatorcontrib>Fernandez, Stefan</creatorcontrib><creatorcontrib>Srisarang, Suchada</creatorcontrib><creatorcontrib>Chotpitayasunondh, Tawee</creatorcontrib><creatorcontrib>Dawood, Fatimah S</creatorcontrib><creatorcontrib>Olsen, Sonja J</creatorcontrib><creatorcontrib>Lindblade, Kim A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kittikraisak, Wanitchaya</au><au>Suntarattiwong, Piyarat</au><au>Ditsungnoen, Darunee</au><au>Pallas, Sarah E</au><au>Abimbola, Taiwo O</au><au>Klungthong, Chonticha</au><au>Fernandez, Stefan</au><au>Srisarang, Suchada</au><au>Chotpitayasunondh, Tawee</au><au>Dawood, Fatimah S</au><au>Olsen, Sonja J</au><au>Lindblade, Kim A</au><au>Ortiz, Justin R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2017-08-24</date><risdate>2017</risdate><volume>12</volume><issue>8</issue><spage>e0183391</spage><epage>e0183391</epage><pages>e0183391-e0183391</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Vaccination is the best measure to prevent influenza. We conducted a cost-effectiveness evaluation of trivalent inactivated seasonal influenza vaccination, compared to no vaccination, in children ≤60 months of age participating in a prospective cohort study in Bangkok, Thailand.
A static decision tree model was constructed to simulate the population of children in the cohort. Proportions of children with laboratory-confirmed influenza were derived from children followed weekly. The societal perspective and one-year analytic horizon were used for each influenza season; the model was repeated for three influenza seasons (2012-2014). Direct and indirect costs associated with influenza illness were collected and summed. Cost of the trivalent inactivated seasonal influenza vaccine (IIV3) including promotion, administration, and supervision cost was added for children who were vaccinated. Quality-adjusted life years (QALY), derived from literature, were used to quantify health outcomes. The incremental cost-effectiveness ratio (ICER) was calculated as the difference in the expected total costs between the vaccinated and unvaccinated groups divided by the difference in QALYs for both groups.
Compared to no vaccination, IIV3 vaccination among children ≤60 months in our cohort was not cost-effective in the introductory year (2012 season; 24,450 USD/QALY gained), highly cost-effective in the 2013 season (554 USD/QALY gained), and cost-effective in the 2014 season (16,200 USD/QALY gained).
The cost-effectiveness of IIV3 vaccination among children participating in the cohort study varied by influenza season, with vaccine cost and proportion of high-risk children demonstrating the greatest influence in sensitivity analyses. Vaccinating children against influenza can be economically favorable depending on the maturity of the program, influenza vaccine performance, and target population.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>28837594</pmid><doi>10.1371/journal.pone.0183391</doi><tpages>e0183391</tpages><orcidid>https://orcid.org/0000-0002-2295-4388</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2017-08, Vol.12 (8), p.e0183391-e0183391 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1932162294 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS) Journals Open Access; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Age Armed forces Biology and Life Sciences Child, Preschool Children Children & youth Childrens health Cohort Studies Collaboration Computer simulation Cost-Benefit Analysis Decision Support Techniques Disease control Disease prevention Economic analysis Health aspects Health care expenditures Humans Immunization Infant Infectious diseases Influenza Influenza vaccines Influenza Vaccines - administration & dosage Influenza Vaccines - economics Laboratories Medicine and Health Sciences Older people Pediatrics People and Places Prevention Promotion Prospective Studies Public health Quality-Adjusted Life Years Risk factors Seasons Sensitivity analysis Social Sciences Studies Thailand Vaccination Vaccines Virology |
| title | Cost-effectiveness of inactivated seasonal influenza vaccination in a cohort of Thai children ≤60 months of age |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T20%3A40%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20inactivated%20seasonal%20influenza%20vaccination%20in%20a%20cohort%20of%20Thai%20children%20%E2%89%A460%20months%20of%20age&rft.jtitle=PloS%20one&rft.au=Kittikraisak,%20Wanitchaya&rft.date=2017-08-24&rft.volume=12&rft.issue=8&rft.spage=e0183391&rft.epage=e0183391&rft.pages=e0183391-e0183391&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0183391&rft_dat=%3Cgale_plos_%3EA501665523%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932162294&rft_id=info:pmid/28837594&rft_galeid=A501665523&rft_doaj_id=oai_doaj_org_article_7d87bd2570db4b0d82f1905a5303857f&rfr_iscdi=true |